Scientific Publications

Intranasal Nanoemulsion Vaccines:

Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. Ganesan S, Acosta H, Brigolin C, Orange K, Trabbic K, Chen C, Lien C, Lin Y, Lin M, Chuang Y, Fattom A, Bitko V PLOS ONE. 2022 Nov 2

A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus. Wang SH, Chen J, Smith D, Cao Z, Acosta H, Fan Y, Ciotti S, Fattom A, Baker JR Jr. Vaccine. 2020 Apr 23;38(19):3537-3544.

Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes. Bernstein DI, Cardin RD, Bravo FJ, Hamouda T, Pullum DA, Cohen G, Bitko V, Fattom A. Vaccine. 2019 Oct 8;37(43):6470-6477.

A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge. Smith D, Streatfield SJ, Acosta H, Ganesan S, Fattom A. Vaccine. 2019 Sep 30;37(42):6162-6170.

Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge. Wang SH, Smith D, Cao Z, Chen J, Acosta H, Chichester JA, Yusibov V, Streatfield SJ, Fattom A, Baker JR Jr. Vaccine. 2019 Mar 14;37(12):1591-1600. Vaccine. 2019.02.002.

Nanoemulsion Adjuvant–Driven Redirection of TH2 Immunity Inhibits Allergic Reactions in Murine Models of Peanut Allergy. Jessica J. O’Konek, Jeffrey J. Landers, Katarzyna W. Janczak, Rishi R. Goel, Anna M. Mondrusov, Pamela T. Wong, James R. Baker, Jr; The Journal of Allergy and Clinical Immunology (2018).

A Novel Nanoemulsion Vaccine Induces Mucosal Interleukin-17 Responses And Confers Protection Upon Mycobacterium Tuberculosis Challenge In Mice. Mushtaq Ahmed, Douglas M. Smith, Tarek Hamouda, Javier Rangel-Moreno, Ali Fattom, Shabaana A. Khader; Vaccine, Volume 35 (2017) 4983-4989.

Immunomodulation Of TH2 Biased Immunity With Mucosal Administration Of Nanoemulsion Adjuvant. Anna U. Bielinska, Jessica J. O’Konek, Katarzyna W. Janczak, James R. Baker Jr.; Vaccine, Volume 34 (2016) 4017-4024.

Formulation, High Throughput In Vitro Screening and In Vivo Functional Characterization of Nanoemulsion-Based Intranasal Vaccine Adjuvants. Pamela T. Wong, Pascale R. Leroueil, Douglas M. Smith, Susan Ciotti, Anna U. Bielinska, Katarzyna W. Janczak, Catherine H. Mullen, Jeffrey V. Groom, Erin M. Taylor, Crystal Passmore, Paul E. Makidon, Jessica J. O’Konek, Andrzej Myc, Tarek Hamouda, James R. Baker, Jr.; PLoS ONE, May 2015, 10(5): e0126120.

Intranasal Nanoemulsion-Based Inactivated Respiratory Syncytial Virus Vaccines Protect Against Viral Challenge In Cotton Rats. Jessica J O’Konek, Paul E Makidon, Jeffrey J Landers, Zhengyi Cao, Carrie-Anne Malinczak, Jessie Pannu, Jennifer Sun, Vira Bitko, Susan Ciotti, Tarek Hamouda, Zbigniew W Wojcinski, Nicholas W Lukacs, Ali Fattom, and James R Baker, Jr; Human Vaccines & Immunotherapeutics 11:12, 2904–2912; December 2015.

Distinct Pathways of Humoral and Cellular Immunity Induced with the Mucosal Administration of a Nanoemulsion Adjuvant. Anna U. Bielinska, Paul E. Makidon, Katarzyna W. Janczak, Luz P. Blanco, Benjamin Swanson, Douglas M. Smith, Tiffany Pham, Zsuzsanna Szabo, Jolanta F. Kukowska-Latallo, and James R. Baker, Jr; The Journal of Immunology, 2014, 192: 2722–2733.

Intranasal Immunization With W805EC Adjuvanted Recombinant RSV Rf-Ptn Enhances Clearance Of Respiratory Syncytial Virus In A Mouse Model. Crystal Passmore, Paul E Makidon, Jessica J O’Konek, Joseph A Zahn, Jessie Pannu, Tarek Hamouda, Vira Bitko, Andrzej Myc, Nicolas W Lukacs, Ali Fattom, and James R Baker, Jr; Human Vaccines & Immunotherapeutics 10:3, 615–622; March 2014.

Nanoemulsion Nasal Adjuvant W805EC Induces Dendritic Cell Engulfment Of Antigen-Primed Epithelial Cells. Andrzej Myca, Jolanta F. Kukowska-Latalloa, Douglas M. Smith, Crystal Passmore, Tiffany Pham, Pamela Wong, Anna U. Bielinska, James R. Baker Jr.; Vaccine 31 (2013) 1072–1079.

Safety and Immunogenicity of a Novel Nanoemulsion Mucosal Adjuvant W805EC Combined with Approved Seasonal Influenza Antigens. L.R. Stanberry, J.K. Simon, C. Johnson, P.L. Robinson, J. Morry, M.R. Flack, S. Gracon, A. Myc, T. Hamouda, J.R. Baker Jr; Vaccine, Volume 30, Issue 2, 5 January 2012, Pages 307–316.

Nanoemulsion Mucosal Adjuvant Uniquely Activates Cytokine Production By Nasal Ciliated Epithelium And Induces Dendritic Cell Trafficking. Paul E. Makidon, Igor M. Belyakov, Luz P. Blanco, Katarzyna W. Janczak, Jeffrey Landers, Anna U. Bielinska, Jeffrey V. Groom and James R. Baker Jr.; European Journal of Immunology. 2012. 42: 1–14.

Nanoemulsion W805EC Improves Immune Responses Upon Intranasal Delivery Of An Inactivated Pandemic H1N1 Influenza Vaccine. Subash C. Das, Masato Hatta, Peter R. Wilker, Andrzej Myc, Tarek Hamouda, Gabrielle Neumann, James R. Baker Jr., Yoshihiro Kawaoka; Vaccine 30 (2012) 6871– 6877.

A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease. Dennis M. Lindell, Susan B. Morris, Maria P. White1, Lara E. Kallal, Phillip K. Lundy, Tarek Hamouda, James R. Baker Jr, Nicholas W. Lukacs; PLoS ONE, July 2011, Volume 6, Issue 7, e21823.

Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based Adjuvant. Tarek Hamouda, Joyce A. Sutcliffe, Susan Ciotti and James R. Baker, Jr., Clinical and Vaccine Immunology, July 2011,p. 1167-1175, Vol. 18, No. 7.

Induction of Th17 Cellular Immunity With a Novel Nanoemulsion Adjuvant. Anna U. Bielinska, Michele Gerber, Luz P. Blanco, Paul E. Makidon, Katarzyna W. Janczak, Michael Beer, Benjamin Swanson, and James R. Baker Jr., Crit Rev Immunol. 2010 ; 30(2): 189–199.

Characterization Of Stability And Nasal Delivery Systems For Immunization With Nanoemulsion-Based Vaccines. Makidon PE, Nigavekar SS, Bielinska AU, Mank N, Shetty AM, Suman J, Knowlton J, Myc A, Rook T, Baker JR Jr., Journal of Aerosol Medicine and Pulmonary Drug Delivery. Volume 23, Number 2, 2010, pp. 77-89.

Efficacy, Immunogenicity and Stability of a Novel Intranasal Nanoemulsion-Adjuvanted Influenza. Tarek Hamouda, Alexander Chepurnov, Nicholas Mank, Jessica Knowlton, Tatiana Chepurnova, Andrzej Myc, Joyce Sutcliffe and James R. Baker, Jr; Human Vaccines 6:7, 1-10; July 2010.

A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine. Ann U Bielinska, Alexander A. chepurnov, Jeffrey J. Landers, Katarzyna W. Janczak, Tatiana S. Chepurnova, Gary D. Luker, and James R. Baker, Jr. Clinical and Vaccine Immunology, Feb 2008, p.348-358.

Nasal Immunization with a Recombinant HIV gp120 and Nanoemulsion Adjuvant Produces TH1 Polarized Responses and Neutralizing Antibodies to Primary HIV Type 1 Isolates. Ann U Bielinska, Katarzyna W. Janczak, Jeffrey J. Landers, David C. Montefiori, and James R. Baker, Jr. AIDS Research and Human Retroviruses, Volume 24, Number 2, 2008.

Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine. Paul E. Makidon, Anna U. Bielinska, Shraddha S. Nigavekar, Katarzyna W. Janczak, Jessica Knowlton, Alison J. Scott, Nicholas Mank, Zhengyi Cao, Sivaprakash Rathinavelu, Michael R. Beer, J. Erby Wilkinson, Luz P. Blanco, Jeffrey J. Landers, James R. Baker, Jr.; PLoS ONE, 8/2008, Volume 3, Issue 8.

Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects against Bacillus anthracis Spore Challenge. Anna U. Bielinska, Katarzyna W. Janczak, Jeffrey J. Landers, Paul Makidon, Laurie E. Sower, Johnny W. Peterson, and James R. Baker, Jr.; Infection and Immunity, p. 4020–4029 Vol. 75, No. 8, (2007).

Development of Immune Response that Protects Mice from Viral Pneumonitis after a Single Intranasal Immunization with Influenza A Virus and Nanoemulsion. Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young K, Chang J, Hamouda T, Olszewski MA, Baker, Jr JR. Vaccine; 21: 3801-3814, (2003).

Prevention of Murine Influenza A Virus Pneumonitis by Surfactant Nanoemulsions. Donovan BW, Reuter JD, Cao Z, Myc A, Johnson KJ, and Baker Jr. Antiviral Chemistry & Chemotherapy; 11: 41-49, (2000).

Nanotechnology-Based Dermatology and Anti-infective Applications:

Screening Of Nanoemulsion Formulations And Identification Of NB-201 As An Effective Topical Antimicrobial For Staphylococcus Aureus In A Mouse Model Of Infected Wounds. Yongyi Fan, MS, Susan Ciotti, PhD, Zhengyi Cao, MD, Rone Eisma, MS, James Baker Jr., MD, Su He Wang, MD.  Military Medicine, 181, 5:259, 2016

Nanoemulsion Therapy for Burn Wounds Is Effective as a Topical Antimicrobial Against Gram-Negative and Gram-Positive Bacteria. Vladislav A. Dolgachev, PhD, Susan M. Ciotti, PhD, Rone Eisma, MS, Stephen Gracon, DVM, MD, J. Erby Wilkinson, DVM, PhD, DACVP, James R. Baker Jr., and Mark R. Hemmila, MD. Journal of Burn Care & Research, 2016 Mar-Apr; 37(2):e104-14

Treatment With A Novel Topical Nanoemulsion (NB-001) Speeds Time To Healing Of Recurrent Cold Sores. Kircik L, Jones TM, Jarratt M, Flack MR, Ijzerman M, Ciotti S, Sutcliffe J, Boivin G, Stanberry LR, Baker JR. Journal of Drugs in Dermatology. 2012 Aug;11(8):970-7

In Vitro Antibacterial Activity Of NB-003 Against Propionibacterium Acnes. J Pannu, A. McCarthy, A. Martin, T. Hamouda, S. Ciotti, L. Ma, J. Sutcliffe, and J. R. Baker, Jr., Antimicrobial Agents and Chemotherapy, Sep 2011; 55: 4211 – 4217

Topical Nanoemulsion Therapy Reduces Bacterial Wound Infection and Inflammation after Burn Injury. Mark R. Hemmila, Aladdein Mattar, Michael A. Taddonio, Saman Arbabi, Tarek Hamouda, Peter A. Ward, Stewart C. Wang, James R. Baker Jr, Surgery, 2010.01.001

NB-002, a Novel Nanoemulsion with Broad Antifungal Activity against Dermatophytes, Other Filamentous Fungi, and Candida albicans. J. Pannu, McCarthy, A. Martin, T. Hamouda, S. Ciotti, A. Fothergill, and J. Sutcliffe, Antimicrobial Agents & Chemotherapy, Aug. 2009, p. 3273–3279 Vol. 53, No. 8

In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species. LiPuma J, Rathinavelu S, Foster B, Keoleian J, Makidon P, Kalikin L, Baker J, Jr., Antimicrobial Agents & Chemotherapy, Jan. 2009, p. 249–255.

Inactivation Of Ebola Virus With A Surfactant Nanoemulsion. A.A. Chepurnov, L.F. Bakulina, A.A. Dadaeva, E.N. Ustinova, T.S. Chepurnova, J.R. Baker, Jr. Acta Tropica 87 (2003) 315-320.

The Fungicidal Activity of Novel Nanoemulsion (X8W60PC) against Clinically Important Yeast and Filamentous Fungi. Myc A, Vanhecke T, Landers JJ, Hamouda T, Baker Jr. JR (2001). Mycopathologia 155: 195-201, (2002).

A Novel Surfactant Nanoemulsion with a Unique Non-irritant Topical Antimicrobial Activity against Bacteria, enveloped Viruses and Fungi. Hamouda T, Myc A, Donovan B, Shih A, Reuter J, Baker J, Jr (2001). Microbiological Research 156: 1-7.

Antimicrobial Mechanism of Action of Surfactant Lipid Preparations in Enteric Gram-negative Bacilli.  Hamouda T, Baker JR Jr (2000) Journal of Applied Microbiology 89:397-403. Download article (2.2mb PDF)

A Novel Surfactant Nanoemulsion with Broad-spectrum Sporicidal Activity against Bacillus Species. Hamouda T, Hayes M, Cao Z, Tonda R, Johnson K, Wright DC, Brisker J, Baker JR Jr (1999). The Journal of Infectious Diseases 180:1939-49.